

# The Trendlines Group

## Investor presentation

---

Steve Rhodes  
Chairman and CEO

Todd Dollinger  
Chairman and CEO

Haim Brosh  
Chief Financial Officer

August 2019

# Legal disclaimer

## Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

# Trendlines: building companies, building value

Life science  
incubators



 trendlines  
medical • agtech • labs

 trendlines  
agrifood innovation centre



 trendlines  
medical • agtech • labs

 trendlines  
medical **singapore**

# Trendlines: building companies, building value

## In-house innovation center of The Trendlines Group

Inventing and developing  
technologies to address  
unmet market needs




# 12 years of portfolio value expansion



\*Portfolio value includes the fair value of investments in portfolio companies accounted for under the equity method

# Carrying value on eve of exit vs. exit value



\*Includes present value of Stimatix GI estimated royalties.

## Exits: estimated returns and IRR

Exit	Company/Description	Acquirer	Estimated Return*	IRR (%)
2017	MitrAssist	Wai Tech (Hong Kong) Holding Ltd.	2.1 X	12
2017	BioSight	Arkin Bio Ventures LP	216.7 X	71
2016	E.T.View Medical	Ambu A/S	1.2 X	5
2014	Stimatix GI	B. Braun SAS	67.6 X**	77
2014	Inspiro Medical	OPKO Health	8.8 X	131
2013	InnoLap Surgical	Teleflex, Inc.	3.2 X	447
2013	FlowSense Medical	Baxter Int'l	4.0 X	280
2011	PolyTouch Medical	Covidien Ltd.	6.7 X	289
<b>Weighted Average</b>			<b>9X</b>	<b>94%</b>

### Notes

\* Estimated return represents the multiple of exit proceeds over Trendlines' investment in the exited company,: (i) our cash investment and (ii) estimated value of services provided to the exited company.

\*\* Exit by Stimatix GI asset sale to B. Braun. Based on the fair value of Stimatix GI (which remains in our portfolio) as of 30 June 2019 compared to our investment at that time.



The background is a light blue-grey gradient. It features a large, stylized globe composed of a grid of small dots, which is partially visible on the left and bottom. Scattered across the upper right are various celestial symbols, including plus signs, crosses, and small circles, some connected by faint lines. A thin, curved line arcs across the middle of the image.

# The Trendlines model



# The Trendlines model: capital leverage\*

**Trendlines' typical investment**      **~US\$1,420,000** per company



Trendlines  
capital

**~US\$120,000**



Government  
grant

**~US\$650,000**




In-kind  
investment at  
cost


**~US\$650,000**  
over two years

\*Model shown is typical capital leverage model for companies in Israel; similar leverage in Singapore. For more details on our model, refer to our Offer document from November 2015 (<http://investors.trendlines.com/~media/Files/T/TrendLines-IR/regulatory-filings/2015/Prospectus.pdf>).

# Trendlines' model: proven, focused company-building timeline



# Trendlines model: intensive support





# Trendlines Labs

- 8 portfolio companies: interVaal, PregnanTech, Hyblate Medical, Limaca, Avir Medical, Continale Medical, EndoSiQ, Szone Medical
- Partnerships in Singapore, Japan, Europe, U.S., China

## Selected Trendlines Labs inventions

Field	Invention	Status
Urology	Reduced infection-risk Foley catheter	Company formed: interVaal (Singapore)
	Stress urinary incontinence (SUI) device	Company formed: Continale Medical (Singapore)
	Bladder mapping	Company formed: EndoSiQ (Singapore)
	Single-use endoscope for removing kidney stones	On the market since 2016
Neurology	Disposable surgical endoscope	Concept
Women's health	Delaying preterm birth	Company formed: PregnanTech (Israel)
Cardiology	Treating atrial fibrillation	Company formed: Hyblate Medical (Israel)
Aging population	At-home monitoring	Portfolio of concepts and products
Diagnostics	Endoscopic ultrasound fine needle biopsy	Company formed: Limaca (Israel)
	Endotracheal tube to reduce ventilator-associated pneumonia	Company formed : Avir Medical (Singapore)
	Electrolyte balance monitoring device	Company formed: Szone Medical (Singapore)



# Management team



**Todd Dollinger**  
Chairman & CEO



**Barak Singer**  
CEO Trendlines Incubators  
Israel



**Nir Goldenberg**  
CEO Trendlines Labs



**Steve Rhodes**  
Chairman & CEO



**Haim Brosh**  
CFO &  
Joint Co. Sec'y.



**Eric Loh**  
CEO Trendlines Medical  
Singapore



**Nitza Kardish, Ph.D.**  
VP The Trendlines Group  
& Vice Chair, AFIC

The background is a light blue-grey gradient. It features a large, stylized globe composed of a grid of small dots, which is partially visible on the left side. Scattered across the upper right portion of the image are various celestial symbols, including plus signs, crosses, and small circles, suggesting a cosmic or global theme.

**Expanding portfolio value**



# Companies\* achieving milestones to create value

Initial Invest.	Company	Technology Dev.	Technology Proven	Follow-On Capital	Clinical/Field Trials	Commercialization	Exits (by Company Start Date)
2008	NeuroQuest						
2009	Stimatrix GI SolChip						BioSight Invest. 2007   Exit 2017
	Magdent						FLOWSENSE Est. 2009   IPO 2010
2010	ProArc Medical Mem-Tech						ETVIEW Est. 2009   IPO 2010
	Leviticus Cardio						ETVIEW Est. 2009   Exit 2016
	ApiFix						PolyTouch Medical Est. 2009   Exit 2011
2011	GreenSpense MiRobot CoreBone						StimatrixGI Medical Solutions Est. 2009   Exit 2014
2012	EdenShield Gordian Surgical						INSPIRO Medical Est. 2010   Exit 2014
	BioFishency						MitraAssist Assisting the Mitral Valve Est. 2011   Exit 2017
	Saturas						
2013	Omeq Medical						Innolapsurgical Est. 2012   Exit 2013
	STS Medical						
	Valentis						
	Arcuro Medical						
	Vensica Medical						
2014	Fidmi Medical						
	VIAqua Therapeutics						
	Escala Medical						
	OrthoSpin						
2015	ElastiMed						
	AquiNovo						
	InPlant Technologies						
	Hargol FoodTech						
2016	CorAlert						
	MetoMotion						
	liberDI						
	Ceretrievie						
	Seeger Surgical Solutions						
	ZygoFix						
	Limaco Medical						
2017	Vessi Medical						
	BIPS Medical						
	FruitSpec						
	InterVaol						
	AlgaHealth						
	AgroScout						
	SetBone Medical						
	PregnanTech						
2018	Ayzer Sense						
	Hyblate Medical						
	IBI-Ag						
	Agam Aquaculture						
	Vvital Biomed						
	Phytolon						
	Avir Medical						
	Continale Medical						
	Medulla Pro						
2019	EndoSiq						

\*53 portfolio companies as at 30 June 2019; 34 written-off portfolio companies not included.

One of our 10 most valuable portfolio companies as at 30 June 2019.

# 10 most valuable portfolio companies

Fair market value of **10 most valuable** portfolio companies  
**~US\$63.0 million, 66%** of total portfolio value of **~US\$95.6 million.\***

Company name	Initial investment	% owned (fully diluted)
ApiFix Ltd.	2011	19.17
Arcuro Medical Ltd.	2013	26.12
BioFishency Ltd.	2013	37.88
ElastiMed Ltd.	2015	36.58
Fidmi Medical Ltd.	2014	48.28
Hargol FoodTech Ltd.	2016	26.54
Leviticus Cardio Ltd.	2010	19.61
Saturas Ltd.	2013	25.45
Stimatix GI Ltd.	2009	27.16
STS Medical Ltd.	2013	28.43

\*As at 30 June 2019, including the fair value of investments in consolidated portfolio companies. Companies listed alphabetically.

# Minimally invasive scoliosis correction system

Minimally invasive scoliosis correction system incorporates a miniature ratchet mechanism for gentle, incremental correction over time

## Achievements

- Completed Series B funding round
- Named winner of MedTechInnovator Pediatric Pitch Event
- Targeted sales in Canada, Europe, Israel, Asia
- Completed >300 successful surgical procedures
- First patients 7 years post-surgery
- Offices in Boston and Israel
- CE mark
- IP: 7 active patent families

Chair: Ed Roschak      CEO: Paul Mraz  
Trendlines' directors: Todd Dollinger, Steve Rhodes



The ApiFix minimally invasive scoliosis correction system

trendlines  
portfolio

medical

revenue  
stage


# A game changer in heart pump technology

Fully Implanted Ventricular Assist Device (FiVAD), powered wirelessly using both internal and external components, allows patients to walk around without any physical impediments for up to 8 hours a day

## Achievements

- Successful First in Human of FiVAD system
- Awarded US\$950,000 grant from BIRD Foundation together with Jarvik Heart, global #3 in the LVAD market
- Prof. Mandeep R. Mehra & Prof. Nir Uriel Join Leviticus Cardio's Scientific Advisory Board
- Fully operational system
- ISO 13485
- Concept validated by key opinion leaders
- Raised US\$9.2 million to date
- IP: 12 issued patents; several pending in the United States

CEO: Michael Zilbershlag  
Trendlines' director: Steve Rhodes



**Leviticus provides the day-to-day power needs of LVADs**



# Low-profile solutions for colostomy management

Low-profile innovative solutions for colostomy management, created to improve the quality of life for people with stomas

## Achievements

- Commercial launch of product and addition of Be 1<sup>®</sup> product on B. Braun website
- B. Braun has established high-volume manufacturing facility
- Completed multiple successful clinical studies
- **Acquired by B. Braun** in 2014 for cash, milestone payments, and future royalties



**B | BRAUN**  
SHARING EXPERTISE

trendlines  
portfolio

medical

★  
exited



# Water treatment system for aquaculture

Cost-effective, all-in-one water treatment system for reduced water use and improved yields in all types of land-based aquaculture systems (extensive, intensive, and recirculated)

## Achievements

- Units operating in 7 countries (Asia, Africa & Middle East)
- Closed US\$2.4 million investment round
- Completed large project in China in June 2018
- Up to 95% reduction in water consumption and 2-5 fold increase in yields
- 2018 sales ~US\$1,350,000
- Signed agreement with the Technion-Israel Institute of Technology for new technology R&D
- Patent in National phase (Israel, China, Europe, India, Brazil)

Co-Founder & Co-CEO: Igal Magen  
Trendlines' directors: Nitza Kardish, Steve Rhodes



The BioFishency all-in-one aquaculture water treatment system

trendlines  
portfolio



# Miniature stem water potential (SWP) sensor




Advanced decision support system for optimal irrigation through a miniature SWP sensor embedded in the trunks of trees, vines, and plants

## Achievements

- Completed successful field trials in California (vineyards, almond, walnut trees)
- New field trials in South Africa (vineyards, almond, apple, citrus)
- Installed ~500 sensors in 3 experimental/10 commercial farms (California, Spain, Israel)
- Established strategic cooperation with Netafim and NaanDanJain
- Received Horizon2020 grant for €1.5 million

CEO: Anat Halgoa Solomon

Trendlines' directors: Todd Dollinger, Steve Rhodes



**Saturas represents an advanced decision support system for optimal irrigation**





# Delivering protein with edible insects



Developing optimized methods and technology to grow large quantities of grasshoppers quickly in captivity

## Achievements

- Launched product Q1 2018
- Completed 16 breeding cycles
- Increased number of life cycles from one to ten in a year
- Multiple award winner (Global Challenges Israel, Next Innovative Move, SEAL, Tel Aviv WeWork, Innovation for Humanity, Get In The Ring Global)
- Developed a climate-controlled infrastructure for growing grasshoppers year round
- Significant media attention

CEO: Dror Tamir

Trendlines' directors: Sarai Kemp, Steve Rhodes




**Hargol established the world's first commercial-scale grasshopper farm**



The background is a light blue-grey gradient. It features a large, stylized globe on the left side, composed of a grid of small dots. The globe is partially obscured by a large, faint, curved line that sweeps across the upper half of the image. In the upper right corner, there are several small, faint symbols: a plus sign, a cross, and a circle. A faint, curved line also sweeps across the lower half of the image, mirroring the one above. The overall aesthetic is clean and modern, with a focus on geometric shapes and subtle patterns.

# Financial highlights

# Key value components



\* Israeli government loans are non-recourse loans which only come due upon exit events.

\*\* Deferred taxes from unrealized portfolio company valuation profits are offset and paid only upon realization of cash from exits.

# Stock overview

Trendlines' SGX share price movement: August 2018 - August 2019 (S\$)



As at 5 Aug 2019	SGX: 42T S\$	OTCQX: TRNLY US\$
Share price	S\$ 0.081	US\$ 3.13
IPO price	S\$ 0.33	—
52-wk high	S\$ 0.118	US\$ 4.22
52-wk low	S\$ 0.076	US\$ 2.70
Market cap	S\$ 49.31 million	US\$ 38.96 million
Shares outstanding	608.7 million*	Each OTCQX ADR = 50 SGX shares
Net asset value per share/ADR	S\$ 0.19	US\$ 7.0

\*On 6 August 2019, the Company announced the completion of a placement, bringing the total number of issued shares from 608,741,749 to 712,360,797.


# Stock performance: Net Asset Value (NAV)

	SGD	USD
NAV per share/ADR*	S\$ 0.19	US\$ 7.00
Price per share/ADR**	S\$ 0.081	\$3.20
% discount to NAV	58%	54%

\*As at 30 June 2019

\*\*Market close as at 5 Aug 2019

# Stock performance: Trendlines vs. Catalyst trends



# Traded peer group & industry comparables

	Price to portfolio (FMV <sup>1</sup> )
IP Group (LSE:IPO)	0.59
Malin Corporation (ISE:MLC)	0.36
Mercia Technologies (AIM:MERC)	1.18
Average price to portfolio	<u>0.71</u>
<b>Trendlines price to portfolio</b>	<b><u>0.37</u></b>


1. Based on market capitalization as at 5 Aug 2019, divided by last available Portfolio Value.

Industry comparables price to book	
707 health care products companies <sup>2</sup> average price/book	3.83
407 farming and agriculture companies <sup>2</sup> average price/book	1.57
<b>Trendlines price to book</b> (5 Aug 2019)	<b>0.42</b>

2. Prof. Aswath Damodaran, New York University, 5 Jan 2019 [people.stern.nyu.edu/adamodar/New\\_Home\\_Page/datacurrent.html](http://people.stern.nyu.edu/adamodar/New_Home_Page/datacurrent.html).



# Factors driving value expansion

- 
- 1 Increasing portfolio companies' value through intense support
  - 2 Building companies for exit
  - 3 Trendlines Labs: creating new IP and new portfolio companies
  - 4 Advancing the Agrifood Innovation Centre in Singapore (AFIC)



# Creating and developing companies **to improve the human condition**

SGX: 42T  
OTCQX: TRNLY

+972.72.260.7000  
[www.trendlines.com](http://www.trendlines.com)



Steve Rhodes, Chairman & CEO  
[steve@trendlines.com](mailto:steve@trendlines.com)

Todd Dollinger, Chairman & CEO  
[todd@trendlines.com](mailto:todd@trendlines.com)

Haim Brosh, Chief Financial Officer  
[haim@trendlines.com](mailto:haim@trendlines.com)

August 2019